CRISPR, CAR-T, and NK: Current applications and future perspectives.

Area of Science:

• Immunology
• Genetics
• Oncology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy is a personalized cancer treatment that reprograms T-cells to target tumor cells.
• While successful in B-cell malignancies, CAR-T therapy's efficacy in solid tumors requires further validation.
• Natural killer (NK) cells are potent cytotoxic lymphocytes crucial for anti-tumor immunity.

Purpose of the Study:

• To review advancements in gene editing technologies for optimizing CAR T-cell and NK cell therapies.
• To explore the potential of CRISPR-Cas9 and similar tools in developing safer and more effective cancer immunotherapies.
• To assess future challenges and opportunities for these next-generation treatments in clinical trials.

Main Methods:

• Investigating the use of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) systems for gene editing in CAR T-cells and NK cells.
• Focusing on methodologies that induce hereditary changes, modify specific genes, and enhance cellular interactions.
• Exploring strategies to create reproducible, safe, and potent allogeneic CAR T-cells for on-demand immunotherapy.

Main Results:

• CRISPR/Cas9 offers adaptable gene editing for activating pathways that improve NK cell and CAR T-cell tumor targeting.
• Gene editing can target negative regulators of T-cells and enable precise genetic modifications.
• Novel approaches aim to enhance the safety, efficacy, and allogeneic potential of CAR T-cell therapies.

Conclusions:

• Next-generation gene editing tools, particularly CRISPR-Cas9, hold significant potential for advancing CAR T-cell and NK cell cancer immunotherapies.
• Optimizing these cellular therapies through precise gene editing is crucial for future clinical applications in solid tumors.
• Continued research and development are essential to overcome challenges and establish these treatments as a foundation for modern cancer therapy.